Fallopian Tube Carcinoma [clinicaltrials_resource:84e23db8f5348f5123f0b20dd7b17e5b]
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00060359]Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer [clinicaltrials:NCT00352300]clinicaltrials:NCT00499252Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy [clinicaltrials:NCT00551265]Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer [clinicaltrials:NCT00814086]OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission [clinicaltrials:NCT00857545]clinicaltrials:NCT00880360Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy [clinicaltrials:NCT00899093]clinicaltrials:NCT00939809clinicaltrials:NCT00968799EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [clinicaltrials:NCT01118052]Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer [clinicaltrials:NCT01139957]clinicaltrials:NCT01202890Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma [clinicaltrials:NCT01381861]Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 [clinicaltrials:NCT01445275]Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma [clinicaltrials:NCT01519869]clinicaltrials:NCT01611766Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy [clinicaltrials:NCT01709487]clinicaltrials:NCT01773889clinicaltrials:NCT01936974clinicaltrials:NCT02033616clinicaltrials:NCT02118285clinicaltrials:NCT02124421Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer [clinicaltrials:NCT02125513]DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission [clinicaltrials:NCT02166905]clinicaltrials:NCT02199171Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery [clinicaltrials:NCT02315469]Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma [clinicaltrials:NCT02328716]clinicaltrials:NCT02344095
condition [clinicaltrials_vocabulary:condition]
Fallopian Tube Carcinoma [clinicaltrials_resource:84e23db8f5348f5123f0b20dd7b17e5b]
Bio2RDF identifier
84e23db8f5348f5123f0b20dd7b17e5b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:84e23db8f5348f5123f0b20dd7b17e5b
identifier
clinicaltrials_resource:84e23db8f5348f5123f0b20dd7b17e5b
title
Fallopian Tube Carcinoma
@en
label
Fallopian Tube Carcinoma [clinicaltrials_resource:84e23db8f5348f5123f0b20dd7b17e5b]
@en